Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes

References

• Ariyoshi N., Miyamoto M., Umetsu Y., Kunitoh H., Dosaka-Akita H., Sawamura Y., et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 2002; 11(9)890–894
   PubMed Web of Science ®Google Scholar
• Ariyoshi N., Miyazaki M., Toide K., Sawamura Y., Kamataki T. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 2001; 281(5)1256–1260
   PubMed Web of Science ®Google Scholar
• Aubin H. J., Bobak A., Britton J. R., Oncken C., Billing C. B., Jr, Gong J., et al. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax 2008; 63(8)717–724
   PubMed Web of Science ®Google Scholar
• Audrain-McGovern J., Al Koudsi N., Rodriguez D., Wileyto E. P., Shields P. G., Tyndale R. F. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics 2007; 119(1)e264–e274
   PubMed Web of Science ®Google Scholar
• Benowitz N. L. Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence. NIDA Res Monogr 1990; 99: 12–29
   PubMedGoogle Scholar
• Benowitz N. L. Nicotine Safety and Toxicity. Oxford University Press, New York 1998
   Google Scholar
• Benowitz N. L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008; 83(4)531–541
   PubMed Web of Science ®Google Scholar
• Benowitz N. L., Jacob P., 3rd. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994; 56(5)483–493
   PubMed Web of Science ®Google Scholar
• Benowitz N. L., Lessov-Schlaggar C. N., Swan G. E., Jacob P., 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 2006a; 79(5)480–488
   PubMed Web of Science ®Google Scholar
• Benowitz N. L., Pomerleau O. F., Pomerleau C. S., Jacob P., 3rd. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res 2003; 5(5)621–624
   PubMed Web of Science ®Google Scholar
• Benowitz N. L., Swan G. E., Jacob P., 3rd, Lessov-Schlaggar C. N., Tyndale R. F. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 2006b; 80(5)457–467
   PubMed Web of Science ®Google Scholar
• Biberman R., Neumann R., Katzir I., Gerber Y. A randomized, controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003; 98(10)1403–1407
   PubMed Web of Science ®Google Scholar
• Cahill, K., Stead, L. F., Lancaster, T. 2007. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 1, CD006103.
   PubMed Web of Science ®Google Scholar
• CDC. 2004. The health consequences of smoking: a report of the Surgeon General. 2004. Atlanta, Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
   Google Scholar
• Coe J. W., Brooks P. R., Vetelino M. G., Wirtz M. C., Arnold E. P., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48(10)3474–3477
   PubMed Web of Science ®Google Scholar
• Damaj M. I., Siu E. C., Sellers E. M., Tyndale R. F., Martin B. R. Inhibition of nicotine metabolism by methoxysalen: pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther 2007; 320(1)250–257
   PubMed Web of Science ®Google Scholar
• David S. P., Brown R. A., Papandonatos G. D., Kahler C. W., Lloyd-Richardson E. E., Munafo M. R., et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 2007; 9(8)821–833
   PubMed Web of Science ®Google Scholar
• Dempsey D., Tutka P., Jacob P., 3rd, Allen F., Schoedel K., Tyndale R. F., et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004; 76(1)64–72
   PubMed Web of Science ®Google Scholar
• Faucette S. R., Hawke R. L., Lecluyse E. L., Shord S. S., Yan B., Laethem R. M., et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28(10)1222–1230
   PubMed Web of Science ®Google Scholar
• Fernandez-Salguero P., Hoffman S. M., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57(3)651–660
   PubMed Web of Science ®Google Scholar
• Fujieda M., Yamazaki H., Saito T., Kiyotani K., Gyamfi M. A., Sakurai M., et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004; 25(12)2451–2458
   PubMed Web of Science ®Google Scholar
• George T. P., Vessicchio J. C., Termine A., Jatlow P. I., Kosten T. R., O'Malley S. S. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003; 53(2)136–143
   PubMed Web of Science ®Google Scholar
• Gonzales D., Rennard S. I., Nides M., Oncken C., Azoulay S., Billing C. B., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized, controlled trial. JAMA 2006; 296(1)47–55
   PubMed Web of Science ®Google Scholar
• Goodz S. D., Tyndale R. F. Genotyping human CYP2A6 variants. Meth Enzymol 2002; 357: 59–69
   PubMed Web of Science ®Google Scholar
• Gourlay, S. G., Stead, L. F., Benowitz, N. L. 2004. Clonidine for smoking cessation. Cochrane Database Syst Rev, 3, CD000058.
   PubMedGoogle Scholar
• Grossman I. Routine pharmacogenetic testing in clinical practice: dream or reality?. Pharmacogenomics 2007; 8(10)1449–1459
   PubMed Web of Science ®Google Scholar
• Gu D. F., Hinks L. J., Morton N. E., Day I. N. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000; 64(Pt 5)383–390
   PubMed Web of Science ®Google Scholar
• Guindon G. E. The cost attributable to tobacco use: a critical review of the literature. World Health Organization, Geneva 2006
   Google Scholar
• Heitjan D. F., Asch D. A., Ray R., Rukstalis M., Patterson F., Lerman C. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J 2008; 8(6)391–399
   PubMed Web of Science ®Google Scholar
• Hesse L. M., He P., Krishnaswamy S., Hao Q., Hogan K., von Moltke L. L., et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14(4)225–238
   PubMedGoogle Scholar
• Ho M. K., Mwenifumbo J. C., Zhao B., Gillam E. M., Tyndale R. F. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 2008; 18(1)67–75
   PubMed Web of Science ®Google Scholar
• Hughes, J. R., Stead, L. F., Lancaster, T. 2007. Antidepressants for smoking cessation. Cochrane Database Syst Rev, 1, CD000031.
   PubMed Web of Science ®Google Scholar
• Iwahashi K., Waga C., Takimoto T. Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior. Neuropsychobiology 2004; 49(2)101–104
   PubMed Web of Science ®Google Scholar
• Jinno H., Tanaka-Kagawa T., Ohno A., Makino Y., Matsushima E., Hanioka N., et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003; 31(4)398–403
   PubMed Web of Science ®Google Scholar
• Johnstone E., Benowitz N., Cargill A., Jacob R., Hinks L., Day I., et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther 2006; 80(4)319–330
   PubMed Web of Science ®Google Scholar
• Jorenby D. E., Leischow S. J., Nides M. A., Rennard S. I., Johnston J. A., Hughes A. R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340(9)685–691
   PubMed Web of Science ®Google Scholar
• Kamataki T., Nunoya K., Sakai Y., Kushida H., Fujita K. Genetic polymorphism of CYP2A6 in relation to cancer. Mutat Res 1999; 428(1–2)125–130
   PubMed Web of Science ®Google Scholar
• Karp I., O'Loughlin J., Hanley J., Tyndale R. F., Paradis G. Risk factors for tobacco dependence in adolescent smokers. Tob Control 2006; 15(3)199–204
   PubMed Web of Science ®Google Scholar
• Kitagawa K., Kunugita N., Katoh T., Yang M., Kawamoto T. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem Biophys Res Commun 1999; 262(1)146–151
   PubMed Web of Science ®Google Scholar
• Kubota T., Nakajima-Taniguchi C., Fukuda T., Funamoto M., Maeda M., Tange E., et al. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 2006; 6(2)115–119
   PubMed Web of Science ®Google Scholar
• Lang T., Klein K., Fischer J., Nussler A. K., Neuhaus P., Hofmann U., et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11(5)399–415
   PubMedGoogle Scholar
• Lea R. A., Dickson S., Benowitz N. L. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol 2006; 30(6)386–389
   PubMed Web of Science ®Google Scholar
• Lee A. M., Jepson C., Hoffmann E., Epstein L., Hawk L. W., Lerman C., et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 2007a; 62(6)635–641
   PubMed Web of Science ®Google Scholar
• Lee A. M., Jepson C., Shields P. G., Benowitz N., Lerman C., Tyndale R. F. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 2007b; 16(6)1312–1314
   PubMed Web of Science ®Google Scholar
• Lee A. M., Tyndale R. F. Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. J Psychopharmacol 2006; 20(4 Suppl)7–14
   PubMedGoogle Scholar
• Lerman C., Shields P. G., Wileyto E. P., Audrain J., Pinto A., Hawk L., et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002; 12(8)627–634
   PubMedGoogle Scholar
• Lerman C., Tyndale R., Patterson F., Wileyto E. P., Shields P. G., Pinto A., et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79(6)600–608
   PubMed Web of Science ®Google Scholar
• Lerman C. E., Schnoll R. A., Munafo M. R. Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med 2007; 33(6 Suppl)S398–S405
   PubMed Web of Science ®Google Scholar
• Levi M., Dempsey D. A., Benowitz N. L., Sheiner L. B. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples. II. Model application. J Pharmacokinet Pharmacodyn 2007; 34(1)23–34
   PubMed Web of Science ®Google Scholar
• Levine R., Kendler M. Millions saved: proven success in global health. Center for Global Development, Washington, DC 2004
   Google Scholar
• Loboz K. K., Gross A. S., Williams K. M., Liauw W. S., Day R. O., Blievernicht J. K., et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 2006; 80(1)75–84
   PubMed Web of Science ®Google Scholar
• Malaiyandi V., Goodz S. D., Sellers E. M., Tyndale R. F. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev 2006a; 15(10)1812–1819
   PubMed Web of Science ®Google Scholar
• Malaiyandi V., Lerman C., Benowitz N. L., Jepson C., Patterson F., Tyndale R. F. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006b; 11(4)400–409
   PubMed Web of Science ®Google Scholar
• Malaiyandi V., Sellers E. M., Tyndale R. F. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005; 77(3)145–158
   PubMed Web of Science ®Google Scholar
• Messina E. S., Tyndale R. F., Sellers E. M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282(3)1608–1614
   PubMed Web of Science ®Google Scholar
• Miksys S., Lerman C., Shields P. G., Mash D. C., Tyndale R. F. Smoking, alcoholism, and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003; 45(1)122–132
   PubMed Web of Science ®Google Scholar
• Minematsu N., Nakamura H., Furuuchi M., Nakajima T., Takahashi S., Tateno H., et al. Limitation of cigarette consumption by CYP2A6*4, *7, and *9 polymorphisms. Eur Respir J 2006; 27(2)289–292
   PubMed Web of Science ®Google Scholar
• Miyamoto M., Umetsu Y., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 1999; 261(3)658–660
   PubMed Web of Science ®Google Scholar
• MMWR. 2007. Cigarette Smoking Adults–—United States, 2006. Mobidity and Mortality Weekly Reports (MMWRs): 56.
   Google Scholar
• Munafo M., Clark T., Johnstone E., Murphy M., Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004; 6(4)583–597
   PubMed Web of Science ®Google Scholar
• Mwenifumbo J. C., Al Koudsi N., Ho M. K., Zhou Q., Hoffmann E. B., Sellers E. M., et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 2008a; 29(5)679–688
   PubMed Web of Science ®Google Scholar
• Mwenifumbo J. C., Lessov-Schlaggar C. N., Zhou Q., Krasnow R. E., Swan G. E., Benowitz N. L., et al. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 2008b; 83(1)115–121
   PubMed Web of Science ®Google Scholar
• Mwenifumbo J. C., Sellers E. M., Tyndale R. F. Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depend 2007; 89(1)24–33
   PubMed Web of Science ®Google Scholar
• Mwenifumbo J. C., Tyndale R. F. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007; 8(10)1385–1402
   PubMed Web of Science ®Google Scholar
• Nakajima M., Fukami T., Yamanaka H., Higashi E., Sakai H., Yoshida R., et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006; 80(3)282–297
   PubMed Web of Science ®Google Scholar
• Nakajima M., Kwon J. T., Tanaka N., Zenta T., Yamamoto Y., Yamamoto H., et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69(1)72–78
   PubMed Web of Science ®Google Scholar
• Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24(11)1212–1217
   PubMed Web of Science ®Google Scholar
• Nunoya K., Yokoi T., Kimura K., Inoue K., Kodama T., Funayama M., et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 1998; 8(3)239–249
   PubMedGoogle Scholar
• O'Loughlin J., Paradis G., Kim W., DiFranza J., Meshefedjian G., McMillan-Davey E., et al. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control 2004; 13(4)422–428
   PubMed Web of Science ®Google Scholar
• Ozaki S., Oyama T., Isse T., Kagawa N., Uramoto H., Sugio K., et al. Smoking cessation program and CYP2A6 polymorphism. Front Biosci 2006; 11: 2590–2597
   PubMed Web of Science ®Google Scholar
• Patten C. J., Smith T. J., Friesen M. J., Tynes R. E., Yang C. S., Murphy S. E. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N’-nitrosonornicotine alpha-hydroxylation by human liver microsomes. Carcinogenesis 1997; 18(8)1623–1630
   PubMed Web of Science ®Google Scholar
• Patterson F., Schnoll R., Wileyto E., Pinto A., Epstein L., Shields P., et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008; 84(3)320–325
   PubMed Web of Science ®Google Scholar
• Peto R., Darby S., Deo H., Silcocks P., Whitley E., Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321(7257)323–329
   PubMed Web of Science ®Google Scholar
• Pianezza M. L., Sellers E. M., Tyndale R. F. Nicotine metabolism defect reduces smoking. Nature 1998; 393(6687)750
   PubMed Web of Science ®Google Scholar
• Rahnasto M., Wittekindt C., Juvonen R. O., Turpeinen M., Petsalo A., Pelkonen O., et al. Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme—an in silico approach. Pharmacogenomics J. 2007; 8(5)328–338
   PubMed Web of Science ®Google Scholar
• Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E. M., et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58(4)747–755
   PubMed Web of Science ®Google Scholar
• Roden D. M., Altman R. B., Benowitz N. L., Flockhart D. A., Giacomini K. M., Johnson J. A., et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006; 145(10)749–757
   PubMed Web of Science ®Google Scholar
• Rollema H., Chambers L. K., Coe J. W., Glowa J., Hurst R. S., Lebel L. A., et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52(3)985–994
   PubMed Web of Science ®Google Scholar
• Sanchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19(4)467–489
   PubMed Web of Science ®Google Scholar
• Schnoll R. A., Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 2006; 11(3)429–444
   PubMedGoogle Scholar
• Schoedel K. A., Hoffmann E. B., Rao Y., Sellers E. M., Tyndale R. F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14(9)615–626
   PubMedGoogle Scholar
• Sellers E. M., Kaplan H. L., Tyndale R. F. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000; 68(1)35–43
   PubMed Web of Science ®Google Scholar
• Sellers E. M., Ramamoorthy Y., Zeman M. V., Djordjevic M. V., Tyndale R. F. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob Res 2003a; 5(6)891–899
   PubMed Web of Science ®Google Scholar
• Sellers E. M., Tyndale R. F. Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci 2000; 909: 233–246
   PubMed Web of Science ®Google Scholar
• Sellers E. M., Tyndale R. F., Fernandes L. C. Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discov Today 2003b; 8(11)487–493
   PubMed Web of Science ®Google Scholar
• Shields A., Lerman C., Sullivan P. Translating emerging research on the genetics of smoking into clinical practice: ethical and social considerations. Nicotine Tob Res 2004; 6(4)675–688
   PubMed Web of Science ®Google Scholar
• Shields A. E., Lerman C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?. Clin Pharmacol Ther 2008; 83(4)635–639
   PubMed Web of Science ®Google Scholar
• Siu E. C., Tyndale R. F. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther 2008; 324(3)992–999
   PubMed Web of Science ®Google Scholar
• Stead, L. F., Perera, R., Bullen, C., Mant, D., Lancaster, T. 2008. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 1, CD000146.
   PubMed Web of Science ®Google Scholar
• Strasser A. A., Malaiyandi V., Hoffmann E., Tyndale R. F., Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res 2007; 9(4)511–518
   PubMed Web of Science ®Google Scholar
• Swan G. E., Benowitz N. L., Jacob P., 3rd, Lessov C. N., Tyndale R. F., Wilhelmsen K., et al. Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Res 2004; 7(5)435–448
   PubMedGoogle Scholar
• Swan G. E., Benowitz N. L., Lessov C. N., Jacob P., 3rd, Tyndale R. F., Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 2005; 15(2)115–125
   PubMed Web of Science ®Google Scholar
• Tyndale, R. F., Pianezza, M. L., Sellers, E. M. 1999. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. Nicotine Tob Res, 1(Suppl 2):S63–S67; discussion, S69–S70.
   PubMedGoogle Scholar
• WHO. 2008. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER package. Geneva: World Health Organization.
   Google Scholar
• Xie H. J., Yasar U., Lundgren S., Griskevicius L., Terelius Y., Hassan M., et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003; 3(1)53–61
   PubMed Web of Science ®Google Scholar
• Yamanaka H., Nakajima M., Fukami T., Sakai H., Nakamura A., Katoh M., et al. CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 2005; 33(12)1811–1818
   PubMed Web of Science ®Google Scholar
• Yamano S., Tatsuno J., Gonzalez F. J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29(5)1322–1329
   PubMed Web of Science ®Google Scholar
• Yamazaki H., Inoue K., Hashimoto M., Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 1999; 73(2)65–70
   PubMed Web of Science ®Google Scholar
• Yamazaki H., Inui Y., Yun C. H., Guengerich F. P., Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13(10)1789–1794
   PubMed Web of Science ®Google Scholar
• Zhang W., Kilicarslan T., Tyndale R. F., Sellers E. M. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 2001; 29(6)897–902
   PubMed Web of Science ®Google Scholar